Photodynamic treatment for multidrug-resistant Gram-negative bacteria: Perspectives for the treatment of Klebsiella pneumoniae infections
- PMID: 31505296
- DOI: 10.1016/j.pdpdt.2019.08.012
Photodynamic treatment for multidrug-resistant Gram-negative bacteria: Perspectives for the treatment of Klebsiella pneumoniae infections
Abstract
The emergence of multi-drug resistance for pathogenic bacteria is one of the most pressing global threats to human health in the 21st century. Hence, the availability of new treatment becomes indispensable to prevent morbidity and mortality caused by infectious agents. This article reviews the antimicrobial properties of photodynamic therapy (PDT), which is based on the use of photosensitizers compounds (PSs). The PSs are non-toxic small molecules, which induce oxidative stress only under excitation with light. Then, the PDT has the advantage to be locally activated using phototherapy devices. We focus on PDT for the Klebsiella pneumoniae, as an example of Gram-negative bacteria, due to its relevance as an agent of health-associated infections (HAI) and a multi-drug resistant bacteria. K. pneumoniae is a fermentative bacillus, member of the Enterobacteriaceae family, which is most commonly associated with producing infection of the urinary tract (UTI) and pneumonia. K. pneumoniae infections may occur in deep organs such as bladder or lungs tissues; therefore, activating light must get access or penetrate tissues with sufficient power to produce effective PDT. Consequently, the rationale for selecting the most appropriate PSs, as well as photodynamic devices and photon fluence doses, were reviewed. Also, the mechanisms by which PDT activates the immune system and its importance to eradicate the infection successfully, are discussed.
Keywords: Antibiotic resistance; Health-associated infections; Klebsiella pneumoniae; Photodynamic therapy; Photosensitizer.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Photodynamic Effectiveness of Copper-Iminopyridine Photosensitizers Coupled to Zinc Oxide Nanoparticles Against Klebsiella pneumoniae and the Bacterial Response to Oxidative Stress.Int J Mol Sci. 2025 Apr 28;26(9):4178. doi: 10.3390/ijms26094178. Int J Mol Sci. 2025. PMID: 40362414 Free PMC article.
-
Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review.J Chemother. 2017 Dec;29(sup1):2-9. doi: 10.1080/1120009X.2017.1380395. J Chemother. 2017. PMID: 29271736 Review.
-
Inhibition of multi-drug resistant Klebsiella pneumoniae: Nanoparticles induced photoinactivation in presence of efflux pump inhibitor.Eur J Pharm Biopharm. 2020 Dec;157:165-174. doi: 10.1016/j.ejpb.2020.10.007. Epub 2020 Oct 26. Eur J Pharm Biopharm. 2020. PMID: 33122117
-
Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in Neonates and Children <5 Years of Age.Pediatr Infect Dis J. 2019 Aug;38(8):812-815. doi: 10.1097/INF.0000000000002344. Pediatr Infect Dis J. 2019. PMID: 31135647
-
Colistin resistance in Klebsiella pneumoniae.Int J Antimicrob Agents. 2014 Jul;44(1):8-15. doi: 10.1016/j.ijantimicag.2014.02.016. Epub 2014 Apr 12. Int J Antimicrob Agents. 2014. PMID: 24794735 Review.
Cited by
-
Use of Antimicrobial Photodynamic Therapy to Inactivate Multidrug-Resistant Klebsiella pneumoniae: Scoping Review.Pharmaceutics. 2024 Dec 23;16(12):1626. doi: 10.3390/pharmaceutics16121626. Pharmaceutics. 2024. PMID: 39771604 Free PMC article.
-
Effective Photodynamic Therapy with Ir(III) for Virulent Clinical Isolates of Extended-Spectrum Beta-Lactamase Klebsiella pneumoniae.Pharmaceutics. 2021 Apr 22;13(5):603. doi: 10.3390/pharmaceutics13050603. Pharmaceutics. 2021. PMID: 33922077 Free PMC article.
-
Effective Treatment against ESBL-Producing Klebsiella pneumoniae through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams.Pharmaceutics. 2021 Nov 8;13(11):1889. doi: 10.3390/pharmaceutics13111889. Pharmaceutics. 2021. PMID: 34834303 Free PMC article.
-
Inactivation of Staphylococcus aureus by antimicrobial photodynamic therapy using 1,9-Dimethyl-Methylene Blue: in vitro and in vivo studies.Lasers Med Sci. 2025 Feb 25;40(1):117. doi: 10.1007/s10103-025-04362-6. Lasers Med Sci. 2025. PMID: 39998562 Free PMC article.
-
Improving the Management and Treatment of Diabetic Foot Infection: Challenges and Research Opportunities.Int J Mol Sci. 2023 Feb 15;24(4):3913. doi: 10.3390/ijms24043913. Int J Mol Sci. 2023. PMID: 36835330 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources